2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 167

Serum Uric Acid Control and Risk of Flare According to Different Cut-Offs in Patients with Gout: Longitudinal Analysis From the King Study of the Italian Society for Rheumatology
Abstract Number: 1174

Severe Adverse Events Associated with Use of Biologic Therapy in Juvenile Idiopathic Arthritis: A Single-Center Study
Abstract Number: 1369

Severe Joint Damage in Psoriatic Arthritis: Mutilans and Ankylosis
Abstract Number: 1053

Severe Joint Injury Assessed by Musculoskeletal Ultrasonography (MSKUS) Predicts the Presence of MRI-Proven Osteitis in Patients with Rheumatoid Arthritis
Abstract Number: 519

Sex-Specific Regulatory T Cell Dysfunction in a Mouse Model of Sjögren Syndrome
Abstract Number: 2422

Sexual Activity and Sexual Functioning Among Women with Systemic Sclerosis Compared to Women From a Population Sample
Abstract Number: 602

Sexual and Reproductive Health Counseling Among Adolescents with Systemic Lupus Erythematosus
Abstract Number: 2006

Sexual Health and Substance Abuse in Adolescents with Rheumatic Conditions
Abstract Number: 1445

Shared and Unique Molecular Features of Nephritis in 3 Models of Murine SLE
Abstract Number: 927

Shared Decision Making in Secondary Care: Rheumatologic Patient’s Perspective
Abstract Number: 939

Shared High Risk of Intensive Care Unit Admission in Three Autoimmune Inflammatory Diseases
Abstract Number: 1823

Short Periods of Glucocorticoid Use Increase the Risk of Gastrointestinal Bleeding
Abstract Number: 1666

Short Term Use of Glucocorticoids Is Not Associated with Acute Risk of Myocardial Infarction
Abstract Number: 2169

Short to Medium Term Safety of Glucocorticoid Therapy in Rheumatoid Arthritis: A Systematic Review and Dose-Response Analysis of Randomized Controlled Trials
Abstract Number: L12

Short- and Long-Term Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Patients with Rheumatoid Arthritis and an Inadequate Response to TNF Inhibitors: Analyses of Pooled Phase 2, Phase 3, and Long-Term Extension Studies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].